+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Blockade of Noradrenergic Neurotransmission with Diethyldithio-carbamic Acid Decreases the mRNA Level of Gonadotropin-Releasing Hormone in the Hypothalamus of Ovariectomized, Steroid-Treated Prepubertal Rats

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We have previously found that progesterone (P) augmented gonadotropin-releasing hormone (GnRH) mRNA levels in the hypothalamus of ovariectomized, estradiol-treated (OVX + E) prepubertal rats. In order to determine whether noradrenergic neurotransmission is involved in the stimulatory effect of P on GnRH gene expression, diethyldithiocarbamic acid (DDC, 500 mg/ kg), a dopamine β-hydroxylase inhibitor was administered i.p. 1 h before P (1 mg) injection into OVX + E treated rats, and the effect of DDC on the P-induced GnRH mRNA levels was examined. A single injection of P into OVX + E primed rats augmented norepinephrine (NE) content, while the administration of DDC effectively blocked the P-induced increase in NE content, along with the increase in dopamine content. Suppression of NE neurotransmission with DDC resulted in a marked decrease in the P-induced GnRH mRNA levels as well as GnRH release in vitro. These results clearly demonstrate that noradrenergic neurotransmission is involved in P-stimulated GnRH gene expression in the rat hypothalamus.

          Related collections

          Author and article information

          S. Karger AG
          08 April 2008
          : 59
          : 6
          : 539-544
          aDepartment of Molecular Biology and SRC for Cell Differentiation, College of Natural Sciences, Seoul National University, Seoul, bDepartment of Biology, College of Natural Sciences, University of Ulsan, Ulsan, cDepartment of Anatomy, College of Medicine, Gyeong Sang National University, Chinju, Korea; dDivision of Clinical and Experimental Endocrinology, University of Göttingen, FRG
          126703 Neuroendocrinology 1994;59:539–544
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Sex Steroids and Regulation of Gonadotropins


          Comment on this article